BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2020 5:30:53 AM | Browse: 917 | Download: 1968
 |
Received |
|
2020-06-30 03:22 |
|
Peer-Review Started |
|
2020-06-30 03:23 |
|
First Decision by Editorial Office Director |
|
2020-10-21 20:23 |
|
Return for Revision |
|
2020-10-21 20:23 |
|
Revised |
|
2020-10-23 01:28 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-11 09:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-12 16:59 |
|
Articles in Press |
|
2020-11-12 16:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-12-24 08:42 |
|
Publish the Manuscript Online |
|
2020-12-27 05:30 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Review |
| Article Title |
Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Soyoun Um, Jueun Ha, Soo Jin Choi, Wonil Oh and Hye Jin Jin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hye Jin Jin, PhD, Director, Director, Senior Researcher, Biomedical Research Institute, MEDIPOST Co., Ltd., 21, Daewangpangyo-ro 644-gil, Bundang-gu, Seongnam 13494, South Korea. genny77@medi-post.co.kr |
| Key Words |
Umbilical cord blood; Mesenchymal stem cell; Stem cell therapy; Immunomodulation; Regenerative medicine; Therapeutic cell manufacturing processing |
| Core Tip |
Umbilical cord blood (UCB) is a primitive and rich source of mesenchymal stem cells (MSCs). UCB-derived MSCs have the potential of exerting profound immunomodulatory effects with the secretion of factors and cytokines. However, the safety and yield of UCB-derived MSCs are still a concern. Next-generation stem cell therapy is necessary, referring to the mass production of efficient stem cells based on the fundamental technology, to improve whole cell processing. |
| Publish Date |
2020-12-27 05:30 |
| Citation |
Um S, Ha J, Choi SJ, Oh W, Jin HJ. Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells. World J Stem Cells 2020; 12(12): 1511-1528 |
| URL |
https://www.wjgnet.com/1948-0210/full/v12/i12/1511.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v12.i12.1511 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
